Business Context and Reporting Period
Company: InspireMD, Inc. (NSPR)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: InspireMD is a medical device company specializing in carotid artery disease treatment. Its portfolio includes the CGuard EPS (marketed internationally) and CGuard Prime (FDA approved June 2025, marketed in the U.S.). The company operates manufacturing facilities in Israel and has headquarters in Miami, Florida.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenues | $3,398 | $1,529 |
| Gross Profit | $687 | $292 |
| Gross Margin | 20.2% | 19.1% |
| Operating Expenses | $14,665 | $11,752 |
| Net Loss | $(13,689) | $(11,166) |
| Net Loss Per Share (Basic/Diluted) | $(0.16) | $(0.22) |
| Cash and Cash Equivalents (End of Period) | $11,362 | $12,383 |
| Marketable Securities | $30,208 | $13,703 |
| Total Current Assets | $48,594 | $N/A |
| Total Current Liabilities | $9,443 | $N/A |
| Net Cash Used in Operating Activities | $(12,337) | $(8,792) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 122% year-over-year to $3.4 million, driven by the U.S. commercial launch of CGuard Prime and continued international growth.
- Expense Increases: Operating expenses rose 24.8% to $14.7 million. Selling and marketing expenses surged 88.4% due to U.S. commercial staffing. R&D expenses increased 17.4% due to higher staff levels and clinical trial costs.
- Net Loss Expansion: Net loss increased 22.6% to $13.7 million, primarily due to a $2.9 million increase in operating expenses.
- Inventory Impairment: Gross margin expansion was partially offset by a $473,000 impairment charge for inventory obsolescence related to the CGuard Prime delivery system.
- Cash Flow: Net cash used in operating activities increased 40.3% to $12.3 million, driven by higher compensation costs. Investing activities provided $14.8 million, primarily from the maturity of $15 million in marketable securities.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. The company does not have sufficient resources to fund operations for the next 12 months without additional financing.
- Product Recall (Unusual Item): In May 2026 (subsequent to period end), the company announced a voluntary recall of the CGuard Prime 135 cm delivery system in the U.S. due to technical success not meeting performance expectations. The company estimates reserves of approximately $700,000 for customer returns and $650,000 for inventory impairment/remediation.
- Geopolitical Risk: The company faces significant risks due to ongoing conflicts in Israel, where its manufacturing facility and key personnel are located. While currently unaffected, escalation could materially harm operations.
- Capital Needs: The company plans to raise capital through equity sales, debt, or strategic partnerships. It has entered a new $75 million Equity Distribution Agreement with BTIG in April 2026.
- Clinical Progress: Enrollment for the CGUARDIANS II pivotal study was completed in Q1 2026. The FDA approved the IDE for the CGUARDIANS III study in May 2026.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline and terms of any new financing required to address the "substantial doubt" regarding going concern status.
- Recall Impact: Monitor the execution of the CGuard Prime recall, including the final cost of remediation and the timeline for FDA approval of design improvements.
- U.S. Commercialization: Assess the sustainability of U.S. revenue growth following the recall and the effectiveness of the direct sales force.
- Geopolitical Exposure: Evaluate contingency plans for manufacturing disruptions in Israel given the volatile regional security situation.
- Warrant Expirations: Review the expiration schedule for outstanding warrants (Series J and K), particularly the Series K warrants expiring in October 2026, and the likelihood of cash exercise.